NorthStar Medical Technologies has secured a significant growth capital facility of up to $185 million from Hercules Capital, marking a pivotal moment for the company's expansion in the radiopharmaceutical industry. This multi-year financing will enable NorthStar to scale its production of no-carrier-added Actinium-225, an isotope critical for targeted cancer therapies, and enhance its manufacturing capabilities.
What Happened
NorthStar has struck a deal with Hercules Capital, securing up to $185 million in financing, with $100 million available immediately. This funding is set to bolster NorthStar's isotope production and expand its clinical and commercial drug manufacturing operations at its integrated radiopharmaceutical campus. The company is at the forefront of producing no-carrier-added Actinium-225, a key isotope used in targeted alpha therapies for cancer treatment.
In January 2026, NorthStar achieved a significant milestone by becoming the first company to produce commercial-scale no-carrier-added Ac-225 using electron-accelerator technology. This breakthrough has positioned NorthStar as a leader in the industry, further supported by a strategic partnership with Convergent to meet the anticipated commercial demand and support late-stage clinical studies.
Moreover, the FDA's acceptance of NorthStar's Drug Master File for no-carrier-added Ac-225 provides a regulatory pathway for pharmaceutical and biotechnology companies to incorporate this isotope into their clinical and commercial radiopharmaceutical programs. NorthStar plans to transition to a higher-capacity Ac-225 production line later in 2026, reinforcing its supply and manufacturing agreements with over 30 pharmaceutical and biotechnology customers.
What This Means for Your Business
For AECM professionals and government contractors, NorthStar's expansion represents new opportunities and competitive advantages in the radiopharmaceutical sector. The increased production capacity of Ac-225 signifies potential supply chain stability and growth for companies relying on this critical isotope. Furthermore, the financial backing from Hercules Capital underscores the confidence in NorthStar's strategic vision and its role as a comprehensive supply-chain partner in the industry.
The expansion also aligns with broader trends in healthcare and pharmaceuticals, where precision medicine and targeted therapies are gaining traction. Companies engaged in the development and manufacturing of radiopharmaceuticals can expect enhanced collaboration opportunities and potential contract developments as NorthStar scales its operations.
What US Operators Should Watch
US operators should closely monitor NorthStar's transition to a higher-capacity Ac-225 production line slated for later in 2026. This timeline is crucial for companies planning to integrate Ac-225 into their drug development pipelines. Additionally, the regulatory acceptance of NorthStar's Drug Master File by the FDA is a pivotal development, providing a clear pathway for regulatory compliance and market entry.
With NorthStar's existing supply and manufacturing agreements, stakeholders should evaluate potential partnerships and procurement opportunities that may arise as the company solidifies its market position. The strategic expansion backed by Hercules Capital could also signal upcoming opportunities for investment and collaboration within the radiopharmaceutical industry.
Source: https://pulse2.com/northstar-secures-up-to-185-million-growth-financing-from-hercules-capital/. Read the original story ->
Is your firm ready for what’s next?
VisioneerIT helps AECM and government contractors modernize operations, achieve compliance, and implement AI.
Explore VisioneerIT Solutions →
